Skip to content

Efficasy and safety of Tauroursodeoxycholic acid in prevention of recurrent bile duct stones after endoscopic clearance of common bile duct stones- Prospective, Randomized, Double-blind,Controlled Trial

Efficasy and safety of Tauroursodeoxycholic acid in prevention of recurrent bile duct stones after endoscopic clearance of common bile duct stones- Prospective, Randomized, Double-blind,Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020800
Enrollment
Unknown
Registered
2019-01-19
Start date
2019-01-30
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common bile duct stones

Interventions

Group 1:Taurolite
Group 2:The placebo

Sponsors

The Second People's Hospital of Lanzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent; 2. men and women aged 18 to 80 years old; 3. A MRCP was performed before the ERCP to diagnose common bile duct stones; 4. patients were endoscopically removed. Postoperatively, common bile duct stones were confirmed. Postoperative angiography suggests no stone residue.

Exclusion criteria

Exclusion criteria: 1. With gallbladder stones; 2. People with severe renal insufficiency; 3. Pregnancy or lactation; 4. Can not complete treatment and follow-up; 5. Duodenal papillary diverticulum; 6. Gastric duodenal ulcer active period; 7. Severe renal insufficiency; 8. Patients with intrahepatic bile duct stones or common bile duct congenital cysts, or biliary tumors, duodenal papillary tumors; 9. Small bowel resection or severe intestinal inflammation; 10. Severe pancreatic disease; 11. Duodenal papillary sphincter incision in ERCP; 12. With history of biliary surgery, and with history of ERCP.

Design outcomes

Primary

MeasureTime frame
Common bile duct stones recurrence;blood routine;

Secondary

MeasureTime frame
liver and kidney function;

Countries

China

Contacts

Public ContactDing Guangrong

The Second People's Hospital of Lanzhou

dingguangrong-j@163.com+86 0931 8362910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026